Annual Statements Open main menu

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. - Quarter Report: 2019 September (Form 10-Q)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q
(Mark One)
 
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED September 28, 2019
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM TO
Commission File No. 001-15943
charlesriverlablogoa03.jpg
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
 
 
 
06-1397316
(State or Other Jurisdiction of
Incorporation or Organization)
 
 
 
(I.R.S. Employer
Identification No.)
251 Ballardvale Street
Wilmington
Massachusetts
 
01887
(Address of Principal Executive Offices)
 
(Zip Code)
 
(Registrant’s telephone number, including area code): (781222-6000
 
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Ticker symbol(s)
Name of each exchange on which registered
Common stock, $0.01 par value
CRL
New York Stock Exchange
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files. Yes  No 
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
 


Emerging growth company



If an emerging growth company, indicate by a check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No 
As of October 25, 2019, there were 48,838,925 shares of the Registrant’s common stock outstanding.



CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

QUARTERLY REPORT ON FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 28, 2019

TABLE OF CONTENTS
Item
 
Page
PART I - FINANCIAL INFORMATION
1
Financial Statements
 
 
Condensed Consolidated Statements of Income (Unaudited) for the three and nine months ended September 28, 2019 and September 29, 2018
 
Condensed Consolidated Statements of Comprehensive Income (Unaudited) for the three and nine months ended September 28, 2019 and September 29, 2018
 
Condensed Consolidated Balance Sheets (Unaudited) as of September 28, 2019 and December 29, 2018
 
Condensed Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 28, 2019 and September 29, 2018
 
Condensed Consolidated Statements of Changes in Equity (Unaudited) for the three and nine months ended September 28, 2019 and September 29, 2018
 
Notes to Unaudited Condensed Consolidated Financial Statements
2
Management’s Discussion and Analysis of Financial Condition and Results of Operations
3
Quantitative and Qualitative Disclosure About Market Risk
4
Controls and Procedures
PART II - OTHER INFORMATION
1
Legal Proceedings
1A
Risk Factors
2
Unregistered Sales of Equity Securities and Use of Proceeds
6
Exhibits
 
 
 
Signatures

1


Special Note on Factors Affecting Future Results
This Quarterly Report on Form 10-Q contains forward-looking statements regarding future events and the future results of Charles River Laboratories International, Inc. that are based on our current expectations, estimates, forecasts and projections about the industries in which we operate and the beliefs and assumptions of our management. Words such as “expect,” “anticipate,” “target,” “goal,” “project,” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “likely,” “may,” “designed,” “would,” “future,” “can,” “could,” and other similar expressions which are predictions of, indicate future events and trends or which do not relate to historical matters, are intended to identify such forward-looking statements. These statements are based on our current expectations and beliefs and involve a number of risks, uncertainties and assumptions that are difficult to predict. These statements also include statements regarding risks and uncertainties associated with the unauthorized access into our information systems reported on April 30, 2019, including the timing and effectiveness of adding enforced security features and monitoring procedures, and the potential revenue and financial impact related to the incident.
For example, we may use forward-looking statements when addressing topics such as: goodwill and asset impairments still under review; future demand for drug discovery and development products and services, including the outsourcing of these services; our expectations regarding stock repurchases, including the number of shares to be repurchased, expected timing and duration, the amount of capital that may be expended and the treatment of repurchased shares; present spending trends and other cost reduction activities by our clients; future actions by our management; the outcome of contingencies; changes in our business strategy, business practices and methods of generating revenue; the investment in, and the development and performance of, our services and products; market and industry conditions, including competitive and pricing trends; our strategic relationships with leading pharmaceutical and biotechnology companies, venture capital investments, and opportunities for future similar arrangements; our cost structure; the impact of acquisitions, including Citoxlab; our expectations with respect to revenue growth and operating synergies (including the impact of specific actions intended to cause related improvements); the impact of specific actions intended to improve overall operating efficiencies and profitability (and our ability to accommodate future demand with our infrastructure), including gains and losses attributable to businesses we plan to close, consolidate, divest or repurpose; changes in our expectations regarding future stock option, restricted stock, performance share units, and other equity grants to employees and directors; expectations with respect to foreign currency exchange; assessing (or changing our assessment of) our tax positions for financial statement purposes; and our liquidity. In addition, these statements include the impact of economic and market conditions on us and our clients; the effects of our cost saving actions and the steps to optimize returns to shareholders on an effective and timely basis; and our ability to withstand the current market conditions.
You should not rely on forward-looking statements because they are predictions and are subject to risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document, or in the case of statements incorporated by reference, on the date of the document incorporated by reference.
Factors that might cause or contribute to such differences include, but are not limited to, those discussed in our Annual Report on Form 10-K for the year ended December 29, 2018, under the sections entitled “Our Strategy,” “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and in this Quarterly Report on Form 10-Q, under the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors,” in our press releases, and other financial filings with the Securities and Exchange Commission. We have no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or risks. New information, future events, or risks may cause the forward-looking events we discuss in this report not to occur.




2



PART I. FINANCIAL INFORMATION
Item 1. Financial Statements

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
(in thousands, except per share amounts)
 
Three Months Ended
 
Nine Months Ended
 
September 28, 2019
 
September 29, 2018
 
September 28, 2019
 
September 29, 2018
Service revenue
$
523,169

 
$
443,038

 
$
1,479,991

 
$
1,226,948

Product revenue
144,782

 
142,257

 
450,097

 
437,618

Total revenue
667,951

 
585,295

 
1,930,088

 
1,664,566

Costs and expenses:
 
 
 
 
 
 
 
Cost of services provided (excluding amortization of intangible assets)
351,894

 
298,018

 
1,014,063

 
844,130

Cost of products sold (excluding amortization of intangible assets)
69,941

 
71,077

 
220,028

 
206,786

Selling, general and administrative
129,509

 
113,033

 
388,024

 
336,936

Amortization of intangible assets
23,805

 
18,805

 
65,611

 
47,813

Operating income
92,802

 
84,362

 
242,362

 
228,901

Other income (expense):
 
 
 
 
 
 
 
Interest income
385

 
230

 
838

 
694

Interest expense
(5,698
)
 
(17,197
)
 
(36,520
)
 
(47,031
)
Other (expense) income, net
(14,254
)
 
5,910

 
(8,161
)
 
24,069

Income from continuing operations, before income taxes
73,235

 
73,305

 
198,519

 
206,633

(Benefit) provision for income taxes
(317
)
 
12,403

 
24,970

 
39,613

Income from continuing operations, net of income taxes
73,552

 
60,902

 
173,549

 
167,020

Income from discontinued operations, net of income taxes

 

 

 
1,506

Net income
73,552

 
60,902

 
173,549

 
168,526

Less: Net income attributable to noncontrolling interests
742

 
534

 
1,878

 
1,818

Net income attributable to common shareholders
$
72,810


$
60,368

 
$
171,671

 
$
166,708

 
 
 
 
 
 
 
 
Earnings per common share
 
 
 
 
 
 
 
Basic:
 
 
 
 
 
 
 
Continuing operations attributable to common shareholders
$
1.49

 
$
1.25

 
$
3.53

 
$
3.43

Discontinued operations
$

 
$

 
$

 
$
0.03

Net income attributable to common shareholders
$
1.49

 
$
1.25

 
$
3.53

 
$
3.47

Diluted:
 
 
 
 
 
 
 
Continuing operations attributable to common shareholders
$
1.46

 
$
1.22

 
$
3.46

 
$
3.36

Discontinued operations
$

 
$

 
$

 
$
0.03

Net income attributable to common shareholders
$
1.46

 
$
1.22

 
$
3.46

 
$
3.39

 
 
 
 
 
 
 
 
Weighted-average number of common shares outstanding:
 
 
 
 
 
 
 
Basic
48,818

 
48,310

 
48,682

 
48,098

Diluted
49,715

 
49,326

 
49,627

 
49,118

 
 
 
 
 
 
 
 
See Notes to Unaudited Condensed Consolidated Financial Statements.

3


CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)
(in thousands)
 
Three Months Ended
 
Nine Months Ended
 
September 28, 2019
 
September 29, 2018
 
September 28, 2019
 
September 29, 2018
Net income
$
73,552

 
$
60,902

 
$
173,549

 
$
168,526

Other comprehensive income (loss):
 
 
 
 
 
 
 
Foreign currency translation adjustment and other
(15,889
)
 
(6,805
)
 
(9,075
)
 
(14,524
)
Amortization of net loss and prior service benefit included in net periodic cost for pension and other post-retirement benefit plans
365

 
615

 
1,113

 
1,864

Comprehensive income, before income taxes
58,028

 
54,712

 
165,587

 
155,866

Less: Income tax expense (benefit) related to items of other comprehensive income
(2,511
)
 
257

 
(1,381
)
 
(341
)
Comprehensive income, net of income taxes
60,539

 
54,455

 
166,968

 
156,207

Less: Comprehensive income (loss) related to noncontrolling interests, net of income taxes
(37
)
 
(74
)
 
1,064

 
886

Comprehensive income attributable to common shareholders, net of income taxes
$
60,576


$
54,529


$
165,904


$
155,321

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See Notes to Unaudited Condensed Consolidated Financial Statements.

4


CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(in thousands, except per share amounts)
 
September 28, 2019
 
December 29, 2018
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
164,759


$
195,442

Trade receivables, net
524,074


472,248

Inventories
155,526


127,892

Prepaid assets
51,274

 
53,447

Other current assets
76,774


48,807

Total current assets
972,407


897,836

Property, plant and equipment, net
1,008,047


932,877

Operating lease right-of-use assets, net
140,359

 

Goodwill
1,521,619


1,247,133

Client relationships, net
620,868

 
537,945

Other intangible assets, net
81,257


72,943

Deferred tax assets
44,831


23,386

Other assets
193,174


143,759

Total assets
$
4,582,562


$
3,855,879

Liabilities, Redeemable Noncontrolling Interests and Equity
 
 
 
Current liabilities:
 
 
 
Current portion of long-term debt and finance leases
$
33,611

 
$
31,416

Accounts payable
107,231

 
66,250

Accrued compensation
130,292

 
137,212

Deferred revenue
166,095

 
145,139

Accrued liabilities
130,015

 
106,925

Other current liabilities
114,402

 
71,280

Total current liabilities
681,646

 
558,222

Long-term debt, net and finance leases
1,882,593

 
1,636,598

Operating lease right-of-use liabilities
116,868

 

Deferred tax liabilities
165,480

 
143,635

Other long-term liabilities
171,243

 
179,121

Total liabilities
3,017,830

 
2,517,576

Commitments and contingencies (Note 17)

 

Redeemable noncontrolling interests
28,345

 
18,525

Equity:
 
 
 
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding

 

Common stock, $0.01 par value; 120,000 shares authorized; 48,976 shares issued and 48,837 shares outstanding as of September 28, 2019, and 48,210 shares issued and 48,209 shares outstanding as of December 29, 2018
490

 
482

Additional paid-in capital
1,514,620

 
1,447,512

Retained earnings
213,767

 
42,096

Treasury stock, at cost, 139 and 1 shares, as of September 28, 2019 and December 29, 2018, respectively
(18,094
)
 
(55
)
Accumulated other comprehensive loss
(178,470
)
 
(172,703
)
Total equity attributable to common shareholders
1,532,313

 
1,317,332

Noncontrolling interest
4,074

 
2,446

Total equity
1,536,387

 
1,319,778

Total liabilities, redeemable noncontrolling interests, and equity
$
4,582,562

 
$
3,855,879

See Notes to Unaudited Condensed Consolidated Financial Statements.

5


CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(in thousands)
 
Nine Months Ended
 
September 28, 2019
 
September 29, 2018
Cash flows relating to operating activities
 
 
 
Net income
$
173,549

 
$
168,526

Less: Income from discontinued operations, net of income taxes

 
1,506

Income from continuing operations, net of income taxes
173,549

 
167,020

Adjustments to reconcile net income from continuing operations to net cash provided by operating activities:
 
 
 
Depreciation and amortization
146,262

 
120,198

Stock-based compensation
43,429

 
35,908

Deferred income taxes
(25,092
)
 
(10,385
)
Gain on venture capital investments
(5,724
)
 
(22,760
)
Other, net
4,865

 
10,036

Changes in assets and liabilities:
 
 
 
Trade receivables, net
(24,491
)
 
(30,318
)
Inventories
(12,981
)
 
(10,340
)
Accounts payable
24,481

 
(5,322
)
Accrued compensation
(23,320
)
 
6,088

Deferred revenue
(1,556
)
 
33,491

Customer contract deposits
(7,586
)
 
34,455

Other assets and liabilities, net
8,423

 
(26,904
)
Net cash provided by operating activities
300,259

 
301,167

Cash flows relating to investing activities
 
 
 
Acquisition of businesses and assets, net of cash acquired
(515,647
)
 
(822,611
)
Capital expenditures
(76,675
)
 
(71,378
)
Purchases of investments and contributions to venture capital investments
(17,664
)
 
(20,535
)
Proceeds from sale of investments
15

 
30,595

Other, net
(660
)
 
(118
)
Net cash used in investing activities
(610,631
)
 
(884,047
)
Cash flows relating to financing activities
 
 
 
Proceeds from long-term debt and revolving credit facility
2,071,175

 
2,392,201

Proceeds from exercises of stock options
26,982

 
30,228

Payments on long-term debt, revolving credit facility, and finance lease obligations
(1,798,620
)
 
(1,832,805
)
Payment of debt financing costs

 
(18,337
)
Purchase of treasury stock
(18,040
)
 
(13,791
)
Other, net
(10,516
)
 

Net cash provided by financing activities
270,981

 
557,496

Discontinued operations
 
 
 
Net cash used in operating activities from discontinued operations

 
(3,735
)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash
8,793

 
4,664

Net change in cash, cash equivalents, and restricted cash
(30,598
)
 
(24,455
)
Cash, cash equivalents, and restricted cash, beginning of period
197,318

 
166,331

Cash, cash equivalents, and restricted cash, end of period
$
166,720

 
$
141,876

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

6


 
Nine Months Ended
 
September 28, 2019
 
September 29, 2018
Supplemental cash flow information:
 
 
 
Cash and cash equivalents
$
164,759

 
$
138,866

Restricted cash included in Other current assets
534

 
426

Restricted cash included in Other assets
1,427

 
2,584

Cash, cash equivalents, and restricted cash, end of period
$
166,720

 
$
141,876

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See Notes to Unaudited Condensed Consolidated Financial Statements.

7





CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (UNAUDITED)
(in thousands)

 
Common Stock
 
Additional Paid-In Capital
 
Retained Earnings
 
Accumulated Other Comprehensive Income (Loss)
 
Treasury Stock
 
Total Equity Attributable to Common Shareholders
 
Noncontrolling Interest
 
Total Equity
Shares
 
Amount
 
 
 
 
Shares
 
Amount
 
 
 
December 29, 2018
48,210

 
$
482

 
$
1,447,512

 
$
42,096

 
$
(172,703
)
 
1

 
$
(55
)
 
$
1,317,332

 
$
2,446

 
$
1,319,778

Net income

 

 

 
55,133

 

 

 

 
55,133

 
469

 
55,602

Other comprehensive income

 

 

 

 
9,903

 

 

 
9,903

 

 
9,903

Adjustment of redeemable noncontrolling interest to redemption value

 

 
(1,451
)
 

 

 

 

 
(1,451
)
 

 
(1,451
)
Issuance of stock under employee compensation plans
674

 
7

 
22,051

 

 

 

 

 
22,058

 

 
22,058

Acquisition of treasury shares

 

 

 

 

 
136

 
(17,760
)
 
(17,760
)
 

 
(17,760
)
Stock-based compensation

 

 
12,899

 

 

 

 

 
12,899

 

 
12,899

March 30, 2019
48,884

 
489

 
1,481,011

 
97,229

 
(162,800
)
 
137

 
(17,815
)
 
1,398,114

 
2,915

 
1,401,029

Net income

 

 

 
43,728

 

 

 

 
43,728

 
383

 
44,111

Other comprehensive loss

 

 

 

 
(3,436
)
 

 

 
(3,436
)
 

 
(3,436
)
Purchase of additional equity interest in and modification of Vital River redeemable noncontrolling interest

 

 
(1,870
)
 

 

 

 

 
(1,870
)
 

 
(1,870
)
Issuance of stock under employee compensation plans
53

 

 
2,148

 

 

 

 

 
2,148

 

 
2,148

Acquisition of treasury shares

 

 

 

 

 
1

 
(123
)
 
(123
)
 

 
(123
)
Stock-based compensation

 

 
16,505

 

 

 

 

 
16,505

 

 
16,505

June 29, 2019
48,937

 
489

 
1,497,794

 
140,957

 
(166,236
)
 
138

 
(17,938
)
 
1,455,066

 
3,298

 
1,458,364

Net income

 

 

 
72,810

 

 

 

 
72,810

 
776

 
73,586

Other comprehensive loss

 

 

 

 
(12,234
)
 

 

 
(12,234
)
 

 
(12,234
)
Issuance of stock under employee compensation plans
39

 
1

 
2,801

 

 

 

 

 
2,802

 

 
2,802

Acquisition of treasury shares

 

 

 

 

 
1

 
(156
)
 
(156
)
 

 
(156
)
Stock-based compensation

 

 
14,025

 

 

 

 

 
14,025

 

 
14,025

September 28, 2019
48,976

 
$
490


$
1,514,620


$
213,767


$
(178,470
)

139


$
(18,094
)

$
1,532,313


$
4,074


$
1,536,387










8





 
Common Stock
 
Additional Paid-In Capital
 
Retained Earnings
 
Accumulated Other Comprehensive Income (Loss)
 
Treasury Stock
 
Total Equity Attributable to Common Shareholders
 
Noncontrolling Interest
 
Total Equity
Shares
 
Amount
 
 
 
 
Shares
 
Amount
 
 
 
December 30, 2017
87,495

 
$
875

 
$
2,560,192

 
$
288,658

 
$
(144,731
)
 
40,093

 
$
(1,659,914
)
 
$
1,045,080

 
$
2,327

 
$
1,047,407

Net income

 

 

 
52,631

 

 

 

 
52,631

 
464

 
53,095

Other comprehensive income

 

 

 

 
23,604

 

 

 
23,604

 

 
23,604

Reclassification due to adoption of ASU 2018-02 Reclass

 

 

 
3,330

 
(3,330
)
 

 

 

 

 

Adjustment due to adoption of ASU 2016-01

 

 

 
1,424

 

 

 

 
1,424

 

 
1,424

Issuance of stock under employee compensation plans
630

 
6

 
20,088

 

 

 

 

 
20,094

 

 
20,094

Acquisition of treasury shares

 

 

 

 

 
126

 
(13,549
)
 
(13,549
)
 

 
(13,549
)
Stock-based compensation

 

 
10,541

 

 

 

 

 
10,541

 

 
10,541

March 31, 2018
88,125

 
881

 
2,590,821

 
346,043

 
(124,457
)
 
40,219

 
(1,673,463
)
 
1,139,825

 
2,791

 
1,142,616

Net income

 

 

 
53,709

 

 

 

 
53,709

 
448

 
54,157

Other comprehensive loss

 

 

 

 
(29,151
)
 

 

 
(29,151
)
 

 
(29,151
)
Issuance of stock under employee compensation plans
96

 
1

 
4,154

 

 

 

 

 
4,155

 

 
4,155

Acquisition of treasury shares

 

 

 

 

 
1

 
(119
)
 
(119
)
 

 
(119
)
Stock-based compensation

 

 
13,547

 

 

 

 

 
13,547

 

 
13,547

June 30, 2018
88,221

 
882

 
2,608,522

 
399,752

 
(153,608
)
 
40,220

 
(1,673,582
)
 
1,181,966

 
3,239

 
1,185,205

Net income

 

 

 
60,368

 

 

 

 
60,368

 
364

 
60,732

Other comprehensive loss

 

 

 

 
(5,840
)
 

 

 
(5,840
)
 

 
(5,840
)
Adjustment of redeemable non-controlling interest to fair value

 

 
(1,111
)
 

 

 

 

 
(1,111
)
 

 
(1,111
)
Issuance of stock under employee compensation plans
94

 
1

 
6,025

 

 

 

 

 
6,026

 

 
6,026

Acquisition of treasury shares

 

 

 

 

 
1

 
(123
)
 
(123
)
 

 
(123
)
Stock-based compensation

 

 
11,820

 

 

 

 

 
11,820

 

 
11,820

September 29, 2018
88,315

 
$
883


$
2,625,256


$
460,120


$
(159,448
)

40,221


$
(1,673,705
)

$
1,253,106


$
3,603


$
1,256,709

Balances may differ compared to prior condensed consolidated balance sheets due to rounding.
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See Notes to Unaudited Condensed Consolidated Financial Statements.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

9

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS


1. BASIS OF PRESENTATION
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Charles River Laboratories International, Inc. (the Company) in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). The year-end condensed consolidated balance sheet data was derived from the Company’s audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for fiscal year 2018. The unaudited condensed consolidated financial statements, in the opinion of management, reflect all normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations.
Use of Estimates
The preparation of unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.
Consolidation
The Company’s unaudited condensed consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation.
The Company’s fiscal year is typically based on 52-weeks, with each quarter composed of 13 weeks ending on the last Saturday on, or closest to, March 31, June 30, September 30, and December 31.
Summary of Significant Accounting Policies
The Company’s significant accounting policies are described in Note 1, “Description of Business and Summary of Significant Accounting Policies” in the Company’s Annual Report on Form 10-K for fiscal year 2018 as well as Note 16, “Leases” in this Quarterly Report on Form 10-Q.
Newly Adopted Accounting Pronouncements
In June 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2018-07, “Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” ASU 2018-07 aligns the accounting for share-based payment awards issued to employees and nonemployees as well as improves financial reporting for share-based payments to nonemployees. This standard became effective for the Company in the three months ended March 30, 2019 and did not have a material impact on the consolidated financial statements and related disclosures.
In August 2017, the FASB issued ASU 2017-12, “Derivatives and Hedging (Topic 815) Targeted Improvements to Accounting for Hedging Activities.” ASU 2017-12 refines and expands hedge accounting for both financial and commodity risks. It also creates more transparency around how economic results are presented, both on the face of the financial statements and in the disclosures. In addition, this ASU makes certain targeted improvements to simplify the application of hedge accounting guidance. This standard became effective for the Company in the three months ended March 30, 2019 and did not have a material impact on the consolidated financial statements and related disclosures.
In February 2016, the FASB issued ASU 2016-02, “Leases.” The standard, including subsequently issued amendments, collectively referred to as Accounting Standards Codification (ASC) 842, “Leases”, established the principles that lessees and lessors will apply to report useful information to users of financial statements about the amount, timing and uncertainty of cash flows arising from a lease. The Company adopted this standard using the modified retrospective transition approach as applied to leases existing as of or entered into after the adoption date (December 30, 2018) in the three months ended March 30, 2019. See Note 16, “Leases” for a discussion of the Company’s adoption of this standard and its impact on the consolidated financial statements and related disclosures.
Newly Issued Accounting Pronouncements
In August 2018, the FASB issued ASU 2018-15, “Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computer Arrangement that is a Service Contract.” ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and

10

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)


hosting arrangements that include an internal-use software license). The ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years and will be applied either retrospectively or prospectively. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures, but does not believe there will be a material impact upon adoption.
In August 2018, the FASB issued ASU 2018-14, “Compensation Retirement Benefits - Defined Benefit Plans -General (Subtopic 715-20).” ASU 2018-14 removes the requirements to disclose the amounts in Accumulated other comprehensive income (loss) expected to be recognized as components of net periodic benefit cost over the next fiscal year and the related party disclosures about the amount of future annual benefits covered by insurance contracts. In addition, the ASU adds the requirement to disclose an explanation for any significant gains and losses related to changes in the benefit obligation for the period. The ASU is effective for fiscal years ending after December 15, 2020 and will be applied on a retrospective basis to all periods presented. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures.
In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement.” ASU 2018-13 removes the disclosure requirement for the amount and reasons for transfers between Level 1 and Level 2 fair value measurements as well as the process for Level 3 fair value measurements. In addition, the ASU adds the disclosure requirements for changes in unrealized gains and losses included in Other comprehensive income (loss) for recurring Level 3 fair value measurements held at the end of the reporting period as well as the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. The ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years and will be applied on a retrospective basis to all periods presented. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures, but does not believe there will be a material impact upon adoption.
In January 2017, the FASB issued ASU 2017-04, “Simplifying the Test for Goodwill Impairment.” The standard simplifies the accounting for goodwill impairment by removing Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. This standard is effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019, and will be applied on a prospective basis. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements and related disclosures, but does not believe there will be a material impact upon adoption.
In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses.” The standard, including subsequently issued amendments, requires a financial asset measured at amortized cost basis, such as accounts receivable, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years, and requires the modified retrospective approach. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures, but does not believe there will be a material impact upon adoption.
2. BUSINESS ACQUISITIONS
Citoxlab
On April 29, 2019, the Company acquired Citoxlab, a non-clinical CRO, specializing in regulated safety assessment services, non-regulated discovery services, and medical device testing. With operations in Europe and North America, the acquisition of Citoxlab further strengthens the Company’s position as a leading, global, early-stage CRO by expanding its scientific portfolio and geographic footprint, which enhances the Company’s ability to partner with clients across the drug discovery and development continuum. The preliminary purchase price for Citoxlab was $527.7 million in cash, subject to certain post-closing adjustments that may change the purchase price. The acquisition was funded through a combination of cash on hand and proceeds from the Company’s Credit Facility under the multi-currency revolving facility. This business is reported as part of the Company’s DSA reportable segment.
The preliminary purchase allocation of $491.0 million, net of $36.7 million of cash acquired was as follows:

11

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)


 
April 29, 2019
 
(in thousands)
Trade receivables (contractual amount of $35,405)
$
35,405

Inventories
5,282

Other current assets (excluding cash)
13,822

Property, plant and equipment
88,912

Goodwill
280,588

Definite-lived intangible assets
162,400

Other long-term assets
20,164

Deferred revenue
(15,278
)
Current liabilities
(46,682
)
Deferred tax liabilities
(27,655
)
Other long-term liabilities
(21,916
)
Redeemable noncontrolling interest
(4,035
)
Total purchase price allocation
$
491,007


The preliminary purchase price allocation is subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed, including certain contracts and obligations. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition.
The breakout of definite-lived intangible assets acquired was as follows:
 
Definite-Lived Intangible Assets
 
Weighted Average Amortization Life
 
(in thousands)
 
(in years)
Client relationships
$
134,600

 
13
Developed technology
19,900

 
3
Backlog
7,900

 
1
Total definite-lived intangible assets
$
162,400

 
12

The goodwill resulting from the transaction, $7.2 million of which is deductible for tax purposes due to a prior asset acquisition, is primarily attributable to the potential growth of the Company’s DSA business from customers introduced through Citoxlab and the assembled workforce of the acquired business.
The Company incurred transaction and integration costs in connection with the acquisition of $1.9 million and $19.1 million for the three and nine months ended September 28, 2019, respectively, which were primarily included in Selling, general and administrative expenses within the unaudited condensed consolidated statements of income.
Beginning on April 29, 2019, Citoxlab has been included in the operating results of the Company. Citoxlab revenue for the three and nine months ended September 28, 2019 was $44.0 million and $74.9 million, respectively. Citoxlab operating income for the three and nine months ended September 28, 2019 was $0.2 million and $2.2 million, respectively.
The following selected unaudited pro forma consolidated results of operations are presented as if the Citoxlab acquisition had occurred as of the beginning of the period immediately preceding the period of acquisition, which is December 31, 2017, after giving effect to certain adjustments. For the nine months ended September 28, 2019, these adjustments included additional amortization of intangible assets and depreciation of fixed assets of $4.8 million, additional interest expense on borrowings of $1.2 million, elimination of intercompany activity and other one-time costs, and the tax impacts of these adjustments. For the nine months ended September 29, 2018, these adjustments included additional amortization of intangible assets and depreciation of fixed assets of $7.3 million, additional interest expense on borrowings of $3.1 million, elimination of intercompany activity and other one-time costs, and the tax impacts of these adjustments.

12

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)


 
Three Months Ended
 
Nine Months Ended
 
September 28, 2019
 
September 29, 2018
 
September 28, 2019
 
September 29, 2018
 
(in thousands)
Revenue
$
667,951

 
$
627,758

 
$
1,992,472

 
$
1,795,312

Net income attributable to common shareholders
$
74,948

 
$
63,919

 
$
189,601

 
$
170,557


These unaudited pro forma results of operations have been prepared for comparative purposes only, and they do not purport to be indicative of the results of operations that actually would have resulted had the acquisition occurred on the dates indicated or that may result in the future. No effect has been given for synergies, if any, that may be realized through the acquisition.
MPI Research
On April 3, 2018, the Company acquired MPI Research, a non-clinical CRO providing comprehensive testing services to biopharmaceutical and medical device companies worldwide. The acquisition enhances the Company’s position as a leading global early-stage CRO by strengthening its ability to partner with clients across the drug discovery and development continuum. The purchase price for MPI Research was $829.7 million in cash. The acquisition was funded by borrowings on the Credit Facility as well as the issuance of the Company’s Senior Notes. See Note 9, “Long-Term Debt and Finance Lease Obligations.” This business is reported as part of the Company’s DSA reportable segment.
The purchase allocation of $800.8 million, net of $27.7 million of cash acquired and a final net working capital adjustment of $1.2 million, was as follows:
 
April 3, 2018
 
(in thousands)
Trade receivables (contractual amount of $35,073)
$
35,073

Inventories
4,463

Other current assets (excluding cash)
5,893

Property, plant and equipment
128,403

Goodwill
441,656

Definite-lived intangible assets
309,200

Other long-term assets
1,081

Deferred revenue
(23,926
)
Current liabilities
(32,885
)
Deferred tax liabilities
(65,945
)
Other long-term liabilities
(2,213
)
Total purchase price allocation
$
800,800


From the date of the acquisition through March 30, 2019, the Company recorded measurement-period adjustments related to the acquisition that resulted in an immaterial change to the purchase price allocation on a consolidated basis. No further adjustments will be made to the purchase price allocation.
The breakout of definite-lived intangible assets acquired was as follows:
 
Definite-Lived Intangible Assets
 
Weighted Average Amortization Life
 
(in thousands)
 
(in years)
Client relationships
$
264,900

 
13
Developed technology
23,400

 
3
Backlog
20,900

 
1
Total definite-lived intangible assets
$
309,200

 
12

The goodwill resulting from the transaction, $4.1 million of which is deductible for tax purposes due to a prior asset acquisition, is primarily attributable to the potential growth of the Company’s DSA business from customers introduced through MPI Research and the assembled workforce of the acquired business.

13

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)


No significant integration costs were incurred in connection with the acquisition for the three and nine months ended September 28, 2019. The Company incurred transaction and integration costs in connection with the acquisition of $0.8 million and $15.3 million for the three and nine months ended September 29, 2018, respectively, which were primarily included in Selling, general and administrative expenses within the unaudited condensed consolidated statements of income.
The following selected unaudited pro forma consolidated results of operations are presented as if the MPI Research acquisition had occurred as of the beginning of the period immediately preceding the period of acquisition, which is January 1, 2017, after giving effect to certain adjustments. For the nine months ended September 29, 2018, these adjustments included additional amortization of intangible assets and depreciation of fixed assets of $11.8 million, additional interest expense on borrowings of $2.8 million, elimination of intercompany activity and other one-time costs, and the tax impacts of these adjustments.
 
September 29, 2018
 
Three Months Ended
 
Nine Months Ended
 
(in thousands)
Revenue
$
585,295

 
$
1,726,683

Net income attributable to common shareholders
59,297

 
168,872


These unaudited pro forma results of operations have been prepared for comparative purposes only, and they do not purport to be indicative of the results of operations that actually would have resulted had the acquisition occurred on the dates indicated or that may result in the future. No effect has been given for synergies, if any, that may be realized through the acquisition.
KWS BioTest Limited
On January 11, 2018, the Company acquired KWS BioTest Limited (KWS BioTest), a CRO specializing in in vitro and in vivo discovery testing services for immuno-oncology, inflammatory and infectious diseases. The acquisition enhances the Company’s discovery expertise, with complementary offerings that provide the Company’s customers with additional tools in the active therapeutic research areas of oncology and immunology. The purchase price for KWS BioTest was $20.3 million in cash and was funded by the Company’s various borrowings. In addition to the initial purchase price, the transaction includes aggregate, undiscounted contingent payments of up to £3.0 million based on future performance. During the three months ended September 29, 2018, the terms of these contingent payments were amended, resulting in a fixed payment of £2.0 million, or $2.6 million, which was paid during the three months ended March 30, 2019. The KWS BioTest business is reported as part of the Company’s DSA reportable segment.
The purchase price allocation of $21.5 million, net of $1.0 million of cash acquired and a final net working capital adjustment of $0.4 million, was as follows:
 
January 11, 2018
 
(in thousands)
Trade receivables (contractual amount of $1,309)
$
1,309

Other current assets (excluding cash)
99

Property, plant and equipment
1,136

Definite-lived intangible assets - client relationships
3,647

Goodwill
17,660

Current liabilities
(1,575
)
Deferred revenue
(151
)
Long-term liabilities
(596
)
Total purchase price allocation
$
21,529


From the date of the acquisition through December 29, 2018, the Company recorded measurement-period adjustments related to the acquisition that resulted in an immaterial change to the purchase price allocation on a consolidated basis. No further adjustments will be made to the purchase price allocation.
The only definite-lived intangible asset relates to client relationships, which will be amortized over a weighted average life of 12 years.
The goodwill resulting from the transaction is primarily attributable to the potential growth of the Company’s DSA business from customers introduced through KWS BioTest and the assembled workforce of the acquired business. The goodwill attributable to KWS BioTest is not deductible for tax purposes.

14

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)


No significant integration costs were incurred in connection with the acquisition for the three and nine months ended September 28, 2019. The Company incurred transaction and integration costs of $0.1 million and $0.6 million in connection with the acquisition for the three and nine months ended September 29, 2018, respectively, which were included in Selling, general and administrative expenses, within the unaudited condensed consolidated statements of income.
Pro forma financial information as well as actual revenue and operating income have not been included because KWS BioTest’s financial results are not significant when compared to the Company’s consolidated financial results.
Other Acquisition
On August 28, 2019, the Company acquired an 80% ownership interest in a supplier that supports the Company’s DSA reportable segment. The remaining 20% interest is a redeemable non-controlling interest. See Note 10, “Equity and Noncontrolling Interests.” The preliminary purchase price was $23.4 million, net of a $4.0 million pre-existing relationship for a supply agreement settled upon acquisition, and subject to certain post-closing adjustments that may change the purchase price. The acquisition was funded through a combination of cash on hand and proceeds from the Company’s Credit Facility under the multi-currency revolving facility. The business is reported as part of the Company’s DSA reportable segment.
The preliminary purchase allocation of $23.1 million, net of $0.3 million of cash acquired was as follows:
 
August 28, 2019
 
(in thousands)
Trade receivables (contractual amount of $189)
$
189

Inventories
7,644

Property, plant and equipment
1,462

Goodwill
12,528

Other long-term assets
11,849

Current liabilities
(300
)
Deferred tax liabilities
(1,331
)
Other long-term liabilities
(238
)
Redeemable noncontrolling interest
(8,740
)
Total purchase price allocation
$
23,063


The purchase price allocation is subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed, including certain contracts and obligations. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition.
The Company incurred transaction and integration costs in connection with the acquisition of $2.1 million and $3.2 million for the three and nine months ended September 28, 2019, respectively, which are primarily included in Selling, general and administrative expenses within the unaudited condensed statements of income.
Pro forma financial information as well as the disclosure of actual results have not been included because these financial results are not significant when compared to the Company’s consolidated financial results.
3. REVENUE FROM CONTRACTS WITH CUSTOMERS
Revenue Recognition
Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer (“transaction price”).
To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the amount to which the Company expects to be entitled. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.
When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Generally, the Company

15

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)


does not extend payment terms beyond one year. Applying the practical expedient, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company’s contracts contained a significant financing component for the nine months ended September 28, 2019 and September 29, 2018.
Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations.
Contracts are often modified to account for changes in contract specifications and requirements. Contract modifications exist when the modification either creates new, or changes existing, enforceable rights and obligations. Generally, when contract modifications create new performance obligations, the modification is considered to be a separate contract and revenue is recognized prospectively. When contract modifications change existing performance obligations, the existing transaction price and measure of progress for the performance obligation to which it relates is recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) on a cumulative catch-up basis.
Product revenue is generally recognized when the customer obtains control of the Company’s product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract. Service revenue is generally recognized over time as the services are delivered to the customer based on the extent of progress towards completion of the performance obligation. The selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. Depending on which better depicts the transfer of value to the customer, the Company generally measures its progress using either cost-to-cost (input method) or right-to-invoice (output method). The Company uses the cost-to-cost measure of progress when it best depicts the transfer of value to the customer which occurs as the Company incurs costs on its contract, generally related to fixed fee service contracts. Under the cost-to-cost measure of progress, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. The costs calculation includes variables such as labor hours, allocation of overhead costs, research model costs, and subcontractor costs. Revenue is recorded proportionally as costs are incurred. The right-to-invoice measure of progress is generally related to rate per unit contracts, as the extent of progress towards completion is measured based on discrete service or time-based increments, such as samples tested or labor hours incurred. Revenue is recorded in the amount invoiced since that amount corresponds directly to the value of the Company’s performance to date.
Disaggregation of Revenue
The following tables disaggregate the Company’s revenue by major business line and timing of transfer of products or services:
 
Three Months Ended

Nine Months Ended
 
September 28, 2019

September 29, 2018

September 28, 2019

September 29, 2018
 
(in thousands)
Major Products/Service Lines:
 
 
 
 
 
 
 
RMS
$
132,546

 
$
126,811

 
$
405,772

 
$
391,195

DSA
420,079

 
352,257

 
1,179,793

 
958,665

Manufacturing
115,326

 
106,227

 
344,523

 
314,706

Total revenue
$
667,951

 
$
585,295

 
$
1,930,088

 
$
1,664,566


16

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)


 
Three Months Ended
 
Nine Months Ended
 
September 28, 2019
 
September 29, 2018
 
September 28, 2019
 
September 29, 2018
 
(in thousands)
Timing of Revenue Recognition:
 
 
 
 
 
 
 
RMS
 
 
 
 
 
 
 
Services and products transferred over time
$
56,243

 
$
49,417

 
$
168,377

 
$
146,947

Services and products transferred at a point in time
76,303

 
77,394

 
237,395

 
244,248

DSA
 
 
 
 
 
 
 
Services and products transferred over time
419,445

 
352,203

 
1,178,874

 
958,174

Services and products transferred at a point in time
634

 
54

 
919

 
491

Manufacturing
 
 
 
 
 
 
 
Services and products transferred over time
36,308

 
31,420

 
102,674

 
92,978

Services and products transferred at a point in time
79,018

 
74,807

 
241,849

 
221,728

Total revenue
$
667,951

 
$
585,295

 
$
1,930,088

 
$
1,664,566


RMS
The RMS business generates revenue through the commercial production and sale of research models and the provision of services related to the maintenance and monitoring of research models and management of clients’ research operations. Revenue from the sale of research models is recognized at a point in time when the customer obtains control of the product, which may be upon shipment or upon delivery based on the shipping terms of a contract. Revenue generated from research models services is recognized over time and is typically based on a right-to-invoice measure of progress (output method) as invoiced amounts correspond directly to the value of the Company’s performance to date.
DSA
The Discovery and Safety Assessment business provides a full suite of integrated drug discovery services directed at the identification, screening and selection of a lead compound for drug development and offers a full range of safety assessment services including bioanalysis, drug metabolism, pharmacokinetics, toxicology and pathology. Discovery and Safety Assessment services revenue is generally recognized over time using the cost-to-cost or right to invoice measures of progress, primarily representing fixed fee service contracts and per unit service contracts, respectively.
Manufacturing
The Manufacturing business includes Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services; Biologics Testing Services (Biologics), which performs specialized testing of biologics; and Avian Vaccine Services (Avian), which supplies specific-pathogen-free chicken eggs and chickens. Species identification service revenue is generally recognized at a point in time as identifications are completed by the Company. Biologics service revenue is generally recognized over time using the cost-to-cost measure of progress. Microbial Solutions and Avian product sales are generally recognized at a point in time when the customer obtains control of the product, which may be upon shipment or upon delivery based on the contractual shipping terms of a contract.
Transaction Price Allocated to Future Performance Obligations
The Company discloses the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as of September 28, 2019. Excluded from the disclosure is the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which revenue is recognized at the amount to which the Company has the right to invoice for services performed.
The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially satisfied) as of September 28, 2019:
 
Revenue Expected to be Recognized in Future Periods
 
Less than 1 Year
 
1 to 3 Years
 
4 to 5 Years
 
Beyond 5 Years
 
Total
 
(in thousands)
DSA
$
163,868

 
$
111,890

 
$
6,641

 
$
409

 
$
282,808

Manufacturing
10,165

 
12,997

 
20

 
8

 
23,190

Total
$
174,033

 
$
124,887

 
$
6,661

 
$
417

 
$
305,998


Contract Balances from Contracts with Customers

17

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)


The timing of revenue recognition, billings and cash collections results in billed receivables (client receivables), contract assets (unbilled revenue), contract liabilities (current and non-current deferred revenue), and customer deposits on the unaudited condensed consolidated balance sheets. The Company’s payment terms are generally 30 days in the United States and consistent with prevailing practice in international markets. A contract asset is recorded when a right to consideration in exchange for goods or services transferred to a customer is conditioned other than the passage of time. Client receivables are recorded separately from contract assets since only the passage of time is required before consideration is due. A contract liability is recorded when consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract. Contract liabilities are recognized as revenue after control of the products or services is transferred to the customer and all revenue recognition criteria have been met. The following table provides information about client receivables, contract assets, and contract liabilities from contracts with customers:
 
September 28, 2019
 
December 29, 2018
 
(in thousands)
Balances from contracts with customers:
 
 
 
Client receivables
$
394,135

 
$
370,131

Contract assets (unbilled revenue)
134,169

 
105,216

Contract liabilities (current and long-term deferred revenue)
191,443

 
179,559

Contract liabilities (customer contract deposits)
36,006

 
38,245


When the Company does not have the unconditional right to advanced billings, both advanced client payments and unpaid advanced client billings are excluded from deferred revenue, with the advanced billings also being excluded from client receivables. As of September 28, 2019, the Company excluded approximately $21 million of unpaid advanced client billings from both client receivables and deferred revenue and approximately $36 million of advanced client payments have been presented as customer contract deposits within other current liabilities in the accompanying unaudited condensed consolidated balance sheets.
Other changes in the contract asset and the contract liability balances during the nine months ended September 28, 2019 were as follows:
(i) Changes due to business combinations:
See Note 2. “Business Acquisitions” for client receivables, contract assets, and contract liabilities that were acquired as part of the Citoxlab acquisition on April 29, 2019.
(ii) Cumulative catch-up adjustments to revenue that affect the corresponding contract asset or contract liability, including adjustments arising from a change in the measure of progress, a change in an estimate of the transaction price (including any changes in the assessment of whether an estimate of variable consideration is constrained), or a contract modification:
During the nine months ended September 28, 2019, an immaterial cumulative catch-up adjustment to revenue was recorded.
(iii) A change in the time frame for a right to consideration to become unconditional (that is, for a contract asset to be recorded as a client receivable):
Approximately 85% of unbilled revenue as of December 29, 2018 was billed during the nine months ended September 28, 2019.
(iv) A change in the time frame for a performance obligation to be satisfied (that is, for the recognition of revenue arising from a contract liability):
Approximately 80% of contract liabilities as of December 29, 2018 were recognized as revenue during the nine months ended September 28, 2019.

18

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)


4. SEGMENT INFORMATION
The Company’s three reportable segments are Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).
The following table presents revenue and other financial information by reportable segment:
 
Three Months Ended
 
Nine Months Ended
 
September 28, 2019
 
September 29, 2018
 
September 28, 2019
 
September 29, 2018
 
(in thousands)
RMS
 
 
 
 
 
 
 
Revenue
$
132,546

 
$
126,811

 
$
405,772

 
$
391,195

Operating income
34,385

 
32,121

 
103,729

 
104,893

Depreciation and amortization
4,895

 
4,811

 
14,198

 
14,565

Capital expenditures
5,818

 
8,166

 
14,979

 
18,105

DSA
 
 
 
 
 
 
 
Revenue
$
420,079

 
$
352,257

 
$
1,179,793

 
$
958,665

Operating income
64,995

 
62,909

 
175,214

 
160,391

Depreciation and amortization
39,898

 
31,433

 
111,231

 
83,262

Capital expenditures
21,141

 
10,800

 
45,130

 
34,496

Manufacturing
 
 
 
 
 
 
 
Revenue
$
115,326

 
$
106,227

 
$
344,523

 
$
314,706

Operating income
39,253

 
33,266

 
103,893

 
95,904

Depreciation and amortization
5,990

 
5,709

 
17,577

 
17,313

Capital expenditures
6,421

 
2,709

 
14,299

 
12,731


Reconciliations of segment operating income, depreciation and amortization, and capital expenditures to the respective consolidated amounts are as follows:
 
Operating Income
 
Depreciation and Amortization
 
Capital Expenditures
 
September 28, 2019
 
September 29, 2018
 
September 28, 2019
 
September 29, 2018
 
September 28, 2019
 
September 29, 2018
 
(in thousands)
Three Months Ended:
 
 
 
 
 
 
 
 
 
 
 
Total reportable segments
$
138,633

 
$
128,296

 
$
50,783

 
$
41,953

 
$
33,380

 
$
21,675

Unallocated corporate
(45,831
)
 
(43,934
)
 
975

 
1,639

 
1,783

 
764

Total consolidated
$
92,802

 
$
84,362

 
$
51,758

 
$
43,592

 
$
35,163

 
$
22,439

 
 
 
 
 
 
 
 
 
 
 
 
Nine Months Ended:
 
 
 
 
 
 
 
 
 
 
 
Total reportable segments
$
382,836

 
$
361,188

 
$
143,006

 
$
115,140

 
$
74,408

 
$
65,332

Unallocated corporate
(140,474
)
 
(132,287
)
 
3,256

 
5,058

 
2,267

 
6,046

Total consolidated
$
242,362

 
$
228,901

 
$
146,262

 
$
120,198

 
$
76,675

 
$
71,378





19

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)


Revenue for each significant product or service offering is as follows:
 
Three Months Ended
 
Nine Months Ended
 
September 28, 2019
 
September 29, 2018
 
September 28, 2019
 
September 29, 2018
 
(in thousands)
RMS
$
132,546

 
$
126,811

 
$
405,772

 
$
391,195

DSA
420,079

 
352,257

 
1,179,793

 
958,665

Manufacturing
115,326

 
106,227

 
344,523

 
314,706

Total revenue
$
667,951

 
$
585,295

 
$
1,930,088

 
$
1,664,566


A summary of unallocated corporate expense consists of the following:
 
Three Months Ended
 
Nine Months Ended
 
September 28, 2019
 
September 29, 2018
 
September 28, 2019
 
September 29, 2018
 
(in thousands)
Stock-based compensation
$
8,752

 
$
7,910

 
$
27,744

 
$
24,517

Compensation, benefits, and other employee-related expenses
18,770

 
20,464

 
54,561

 
56,375

External consulting and other service expenses
4,156

 
4,767

 
12,060

 
12,711

Information technology
3,534

 
3,070

 
10,811

 
8,723

Depreciation
975

 
1,639

 
3,256

 
5,058

Acquisition and integration
5,679

 
1,122

 
23,621

 
15,678

Other general unallocated corporate
3,965

 
4,962

 
8,421

 
9,225

Total unallocated corporate expense
$
45,831

 
$
43,934

 
$
140,474

 
$
132,287


Other general unallocated corporate expense consists of costs associated with departments such as senior executives, corporate accounting, legal, tax, human resources, treasury, and investor relations.
Revenue by geographic area is as follows:
 
U.S.
 
Europe
 
Canada
 
Asia Pacific
 
Other
 
Consolidated
 
(in thousands)
Three Months Ended:
 
 
 
 
 
 
 
 
 
 
 
September 28, 2019
$
373,094

 
$
184,685

 
$
71,984

 
$
36,698

 
$
1,490

 
$
667,951

September 29, 2018
336,811

 
159,473

 
53,665

 
34,062

 
1,284

 
585,295

Nine Months Ended:
 
 
 
 
 
 
 
 
 
 
 
September 28, 2019
$
1,091,194

 
$
533,820

 
$
194,865

 
$
106,090

 
$
4,119

 
$
1,930,088

September 29, 2018
919,807

 
481,955

 
153,802

 
104,817

 
4,185

 
1,664,566


Included in the Asia Pacific category above are operations located in China, Japan, Korea, Australia, Singapore, and India. Included in the Other category above are operations located in Brazil and Israel. Revenue represents sales originating in entities physically located in the identified geographic area.

20

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)


5. SUPPLEMENTAL BALANCE SHEET INFORMATION
The composition of trade receivables, net is as follows:
 
September 28, 2019
 
December 29, 2018
 
(in thousands)
Client receivables
$
394,135

 
$
370,131

Unbilled revenue
134,169

 
105,216

Total
528,304

 
475,347

Less: Allowance for doubtful accounts
(4,230
)
 
(3,099
)
Trade receivables, net
$
524,074

 
$
472,248


The composition of inventories is as follows:
 
September 28, 2019
 
December 29, 2018
 
(in thousands)
Raw materials and supplies
$
23,670

 
$
22,378

Work in process
36,851

 
21,732

Finished products
95,005

 
83,782

Inventories
$
155,526

 
$
127,892


The composition of other current assets is as follows:
 
September 28, 2019
 
December 29, 2018
 
(in thousands)
Prepaid income tax
$
75,019

 
$
47,157

Investments
855

 
885

Restricted cash
534

 
465

Other
366

 
300

Other current assets
$
76,774

 
$
48,807


The composition of other assets is as follows:
 
September 28, 2019
 
December 29, 2018
 
(in thousands)
Venture capital investments
$
100,553

 
$
87,545

Other investments
13,045

 
1,046

Life insurance policies
35,861

 
32,340

Restricted cash
1,427

 
1,411

Other
42,288

 
21,417

Other assets
$
193,174

 
$
143,759


The composition of other current liabilities is as follows:
 
September 28, 2019
 
December 29, 2018
 
(in thousands)
Current portion of operating lease right-of-use liabilities
$
20,032

 
$

Accrued income taxes
44,121

 
24,120

Customer contract deposits
36,006

 
38,245

Other
14,243

 
8,915

Other current liabilities
$
114,402

 
$
71,280



21

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)


The composition of other long-term liabilities is as follows:
 
September 28, 2019
 
December 29, 2018
 
(in thousands)
U.S. Transition Tax
$
52,066

 
$
52,064

Long-term pension liability
29,028

 
24,671

Accrued executive supplemental life insurance retirement plan
37,328

 
36,086

Long-term deferred revenue
25,348

 
34,420

Other
27,473

 
31,880

Other long-term liabilities
$
171,243

 
$
179,121


6. VENTURE CAPITAL AND OTHER INVESTMENTS
The Company invests in several venture capital funds that invest in start-up companies, primarily in the life sciences industry. The Company’s ownership interest in these funds ranges from less than 1% to 12.0%. The Company accounts for the investments in limited partnerships (LPs), which are variable interest entities, under the equity method of accounting. For publicly-held investments in the LPs, the Company adjusts for changes in fair market value based on reported share holdings at the end of each fiscal quarter. The Company is not the primary beneficiary because it has no power to direct the activities that most significantly affect the LPs’ economic performance. The Company accounts for the investments in limited liability companies, which are not variable interest entities, under the equity method of accounting.
Venture capital investments were $100.6 million and $87.5 million as of September 28, 2019 and December 29, 2018, respectively. The Company’s total commitment to the venture capital funds as of September 28, 2019 was $128.1 million, of which the Company funded $77.4 million through that date. The Company received dividends totaling $0.2 million and $5.6 million for the three months ended September 28, 2019 and September 29, 2018, respectively. The Company received dividends totaling $1.8 million and $14.1 million for the nine months ended September 28, 2019 and September 29, 2018, respectively. The Company recognized losses of $0.6 million and gains of $5.4 million related to the venture capital investments for the three months ended September 28, 2019 and September 29, 2018, respectively. The Company recognized gains of $5.7 million and $22.8 million related to the venture capital investments for the nine months ended September 28, 2019 and September 29, 2018, respectively. Gains and losses are recorded in Other income, net in the accompanying unaudited condensed consolidated statements of income.
The Company also invests, with minority positions, directly in equity of predominantly privately-held companies. These investments are reported at fair value or under the equity method of accounting, as appropriate. Equity investments that do not have readily determinable fair values are generally recorded at cost, plus or minus certain adjustments. Other investments were $13.0 million and $1.0 million as of September 28, 2019 and December 29, 2018, respectively. The Company recognized an insignificant amount of gains and losses related to these investments for the three and nine months ended September 28, 2019 and September 29, 2018. Gains and losses from other investments are recorded in Other income, net in the accompanying unaudited consolidated statements of income.
7. FAIR VALUE
The Company has certain assets and liabilities recorded at fair value, which have been classified as Level 1, 2, or 3 within the fair value hierarchy:
Level 1 - Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access,
Level 2 - Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, and foreign currency spot rates,
Level 3 - Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
The fair value hierarchy level is determined by asset and class based on the lowest level of significant input. The observability of inputs may change for certain assets or liabilities. This condition could cause an asset or liability to be reclassified between levels. The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. During the nine months ended September 28, 2019 and September 29, 2018, there were no transfers between levels.

22

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)


Valuation methodologies used for assets and liabilities measured or disclosed at fair value are as follows:
Cash equivalents - Valued at market prices determined through third-party pricing services;
Mutual funds - Valued at the unadjusted quoted net asset value of shares held by the Company;
Foreign currency forward contracts - Valued using market observable inputs, such as forward foreign exchange points and foreign exchanges rates;
Life insurance policies - Valued at cash surrender value based on the fair value of underlying investments;
Debt instruments - The book value of the Company’s term and revolving loans, which are variable rate loans carried at amortized cost, approximates the fair value based on current market pricing of similar debt. The book value of the Company’s 5.5% Senior Notes (Senior Notes) due in 2026, which are fixed rate debt, are carried at amortized cost. Fair value of the Senior Notes is based on quoted market prices and on borrowing rates available to the Company; and
Contingent consideration - Valued based on a probability weighting of the future cash flows associated with the potential outcomes.
Assets and liabilities measured at fair value on a recurring basis are summarized below:
 
September 28, 2019
 
Level 1
 
Level 2
 
Level 3
 
Total
 
(in thousands)
Cash equivalents
$

 
$
436

 
$

 
$
436

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contract

 
778

 

 
778

Life insurance policies

 
28,207

 

 
28,207

Total assets measured at fair value
$

 
$
29,421

 
$

 
$
29,421

 
 
 
 
 
 
 
 
Other current liabilities measured at fair value:
 
 
 
 
 
 
 
Contingent consideration
$

 
$

 
$
692

 
$
692

 
December 29, 2018
 
Level 1
 
Level 2
 
Level 3
 
Total
 
(in thousands)
Cash equivalents
$

 
$
45,982

 
$

 
$
45,982

Other assets:
 
 
 
 
 
 
 
Life insurance policies

 
24,541

 

 
24,541

Total assets measured at fair value
$

 
$
70,523

 
$

 
$
70,523

 
 
 
 
 
 
 
 
Other current liabilities:
 
 
 
 
 
 
 
Contingent consideration
$

 
$

 
$
3,033

 
$
3,033

Foreign currency forward contract

 
1,319

 

 
1,319

Total liabilities measured at fair value
$

 
$
1,319

 
$
3,033

 
$
4,352



23

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)


Contingent Consideration
The following table provides a rollforward of the contingent consideration related to previous business acquisitions. See Note 2, “Business Acquisitions.”
 
Nine Months Ended
 
September 28, 2019
 
September 29, 2018
 
(in thousands)
Beginning balance
$
3,033

 
$
298

Additions
2,869

 
3,315

Payments
(5,252
)
 

Foreign currency translation
42

 
(213
)
Ending balance
$
692

 
$
3,400


The unobservable inputs used in the fair value measurement of the Company’s contingent consideration are the probabilities of successful achievement of certain financial targets and a discount rate. Increases or decreases in any of the probabilities of success would result in a higher or lower fair value measurement, respectively. Increases or decreases in the discount rate would result in a lower or higher fair value measurement, respectively.
Debt Instruments
The book value of the Company’s term and revolving loans, which are variable rate loans carried at amortized cost, approximates the fair value based on current market pricing of similar debt. As the fair value is based on significant other observable inputs, including current interest and foreign currency exchange rates, it is deemed to be Level 2 within the fair value hierarchy.
As of both September 28, 2019 and December 29, 2018, the book value of the Company’s Senior Notes, which is a fixed rate obligation carried at amortized cost, was $500.0 million. The fair value of the Company’s Senior Notes as of September 28, 2019 and December 29, 2018 was $530.0 million and $495.0 million, respectively. Fair value is based on quoted market prices as well as borrowing rates available to the Company. As the fair value is based on significant other observable outputs, it is deemed to be Level 2 within the fair value hierarchy.
8. GOODWILL AND INTANGIBLE ASSETS
Goodwill
The following table provides a rollforward of the Company’s goodwill:
 
 
 
Adjustments to Goodwill
 
 
 
December 29, 2018
 
Acquisitions
 
Foreign Exchange
 
September 28, 2019
 
(in thousands)
RMS
$
56,968

 
$

 
$
(761
)
 
$
56,207

DSA
1,051,470

 
293,116

 
(13,660
)
 
1,330,926

Manufacturing
138,695

 

 
(4,209
)
 
134,486

Goodwill
$
1,247,133

 
$
293,116

 
$
(18,630
)
 
$
1,521,619


The increase in goodwill during the nine months ended September 28, 2019 related primarily to the acquisition of Citoxlab in the DSA reportable segment and the impact of foreign exchange.

24

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)


Intangible Assets, Net
The following table displays intangible assets, net by major class:
 
September 28, 2019
 
December 29, 2018
 
Gross
 
Accumulated Amortization
 
Net
 
Gross
 
Accumulated Amortization
 
Net
 
(in thousands)
Backlog
$
28,716

 
$
(23,969
)
 
$
4,747

 
$
20,900

 
$
(18,691
)
 
$
2,209

Technology
119,180

 
(52,291
)
 
66,889

 
101,506

 
(41,870
)
 
59,636

Trademarks and trade names
8,108

 
(4,724
)
 
3,384

 
8,331

 
(4,640
)
 
3,691

Other
17,850

 
(11,613
)
 
6,237

 
17,448

 
(10,041
)
 
7,407

Other intangible assets
173,854

 
(92,597
)
 
81,257

 
148,185

 
(75,242
)
 
72,943

Client relationships
919,738

 
(298,870
)
 
620,868

 
791,725

 
(253,780
)
 
537,945

Intangible assets
$
1,093,592

 
$
(391,467
)
 
$
702,125

 
$
939,910

 
$
(329,022
)
 
$
610,888


The increase in intangible assets, net during the nine months ended September 28, 2019 related primarily to the acquisition of Citoxlab.
9. LONG-TERM DEBT AND FINANCE LEASE OBLIGATIONS
Long-Term Debt and Finance Lease Obligations
Long-term debt, net and finance leases consists of the following:
 
September 28, 2019
 
December 29, 2018
 
(in thousands)
Term loans
$
703,125

 
$
731,250

Revolving facility
691,459

 
397,452

2026 Senior Notes
500,000

 
500,000

Other debt
5,692

 
26,286

Finance leases (Note 16)
29,712

 
29,240

Total debt and finance leases
1,929,988

 
1,684,228

Less:
 
 
 
Current portion of long-term debt
30,609

 
28,228

Current portion of finance leases (Note 16)
3,002

 
3,188

Current portion of long-term debt and finance leases
33,611

 
31,416

Long-term debt and finance leases
1,896,377

 
1,652,812

Debt discount and debt issuance costs
(13,784
)
 
(16,214
)
Long-term debt, net and finance leases
$
1,882,593

 
$
1,636,598


As of September 28, 2019 and December 29, 2018, the weighted average interest rate on the Company’s debt was 3.33% and 4.24%, respectively.
Term Loans and Revolving Facility
On March 26, 2018, the Company amended and restated its $1.65 billion credit facility creating a $2.3 billion credit facility (Credit Facility). The amendment extended the maturity date and provided for a $750.0 million term loan and a $1.55 billion multi-currency revolving facility. The amendment was accounted for as a debt modification. In connection with the transaction, the Company capitalized approximately $6.2 million within Long-term debt, net and finance leases in the accompanying unaudited condensed consolidated balance sheets and expensed approximately $1.0 million of debt issuance costs recorded within Interest expense in the accompanying unaudited condensed consolidated statements of income for the year ended 2018. On September 25, 2019 the Company amended and restated the Credit Facility for certain administrative matters.
The term loan facility matures in 19 quarterly installments with the last installment due March 26, 2023. The revolving facility matures on March 26, 2023, and requires no scheduled payment before that date.
On October 23, 2019, the Company prepaid $500.0 million of the term loan with proceeds from a $500.0 million unregistered private offering (see 2028 Senior Notes Offering below). Additionally, on November 4, 2019, the Company amended and

25

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)


restated the Credit Facility to increase the multi-currency revolving facility by $500.0 million, from $1.55 billion to $2.05 billion. The amount outstanding under the multi-currency revolving facility has not significantly changed since September 28, 2019. Under specified circumstances, the Company has the ability to increase the term loan and/or revolving facility by up to $1.0 billion in the aggregate.
The interest rates applicable to the term loan and revolving facility under the Credit Facility are, at the Company’s option, equal to either the base rate (which is the higher of (1) the prime rate, (2) the federal funds rate plus 0.50%, or (3) the one-month adjusted LIBOR rate plus 1.0%) or the adjusted LIBOR rate, plus an interest rate margin based upon the Company’s leverage ratio.
The Credit Facility includes certain customary representations and warranties, events of default, notices of material adverse changes to the Company’s business and negative and affirmative covenants. These covenants include (1) maintenance of a ratio of consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) less capital expenditures to consolidated cash interest expense, for any period of four consecutive fiscal quarters, of no less than 3.50 to 1.0 as well as (2) maintenance of a ratio of consolidated indebtedness to consolidated EBITDA for any period of four consecutive fiscal quarters, of no more than 4.00 to 1.0. As of September 28, 2019, the Company was compliant with all covenants.
The obligations of the Company under the Credit Facility are collateralized by substantially all of the assets of the Company.
During the three and nine months ended September 28, 2019, the Company had multiple U.S. dollar denominated loans borrowed by a non-U.S. Euro functional currency entity under the Company’s Credit Facility, which ranged from $300 million to $350 million. This resulted in foreign currency losses recognized in Other income, net of $12.1 million during the three months ended September 28, 2019 and $14.9 million during the nine months ended September 28, 2019. The Company entered into foreign exchange forward contracts to limit its foreign currency exposures related to these borrowings. As of September 28, 2019, the Company did not have any outstanding borrowings in a currency different than its respective functional currency. See Note 14, “Foreign Currency Contracts”, for further discussion.
Base Indenture for Senior Notes Offerings
On April 3, 2018, the Company entered into an indenture (Base Indenture) with MUFG Union Bank, N.A., (Trustee). The purpose of the Indenture was to allow the Company the ability to issue senior notes. The Company has entered into two supplemental indentures in connection with two unregistered offerings, which are described below.
The Indenture contains certain covenants including, but not limited to, limitations and restrictions on the ability of the Company and its U.S. subsidiaries to (i) create certain liens, (ii) enter into any Sale and Leaseback Transaction (as defined in the Indenture) with respect to any property, and (iii) merge, consolidate, sell or otherwise dispose of all or substantially all of their assets. These covenants are subject to a number of conditions, qualifications, exceptions and limitations. Any event of default, as defined, could result in the acceleration of the repayment of the obligations.
2026 Senior Notes Offering
On April 3, 2018, the Company entered into the first supplemental indenture (First Supplemental Indenture) with the Trustee in connection with an offering of $500.0 million in aggregate principal amount of the Company’s 5.5% Senior Notes (2026 Senior Notes), due in 2026, in an unregistered offering. Under the terms of the First Supplemental Indenture, interest on the Senior Notes is payable semi-annually on April 1 and October 1, beginning on October 1, 2018. The 2026 Senior Notes are guaranteed fully and unconditionally, jointly and severally on a senior unsecured basis by the Company and certain of its U.S. subsidiaries. In connection with the transaction, the Company incurred $7.4 million of debt issuance costs within Long-term debt, net and finance leases in the accompanying unaudited condensed consolidated balance sheets.
The Company may redeem all or part of the 2026 Senior Notes at any time prior to April 1, 2021, at its option, at a redemption price equal to 100% of the principal amount of such Senior Notes plus the Applicable Premium (as defined in the First Supplemental Indenture). The Company may also redeem up to 40% of the Senior Notes with the proceeds of certain equity offerings completed before April 1, 2021, at a redemption price equal to 105.5% of the principal amount of such 2026 Senior Notes. On or after April 1, 2021, the Company may on any one or more occasions redeem all or a part of the 2026 Senior Notes, at the redemption prices specified in the Indenture based on the applicable date of redemption. Upon the occurrence of a Change of Control Triggering Event (as defined in the Indenture), the Company will be required to offer to repurchase the 2026 Senior Notes at a purchase price equal to 101% of the aggregate principal amount of such 2026 Senior Notes. Any redemption of the 2026 Senior Notes would also require settlement of accrued and unpaid interest, if any, up to but excluding the redemption date.
Net proceeds from the 2026 Senior Notes of $493.8 million were used to partially repay the outstanding revolving credit facility on April 3, 2018 as well as fund the acquisition of MPI Research.
2028 Senior Notes Offering
On October 23, 2019, the Company entered into a second supplemental indenture (Second Supplemental Indenture) with the Trustee in connection with the offering of $500.0 million in aggregate principal amount of the Company’s 4.25% Senior Notes

26

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)


(2028 Senior Notes), due in 2028, in an unregistered offering. Under the terms of the Second Supplemental Indenture, interest on the 2028 Senior Notes is payable semi-annually on May 1 and November 1, beginning on May 1, 2020. The 2028 Senior Notes are guaranteed fully and unconditionally, jointly and severally on a senior unsecured basis by the Company and certain of its U.S. subsidiaries. In connection with the transaction, the Company incurred approximately $6 million of debt issuance costs, which were capitalized upon the 2028 Senior Notes issuance on October 23, 2019.
The Company may redeem all or part of the 2028 Senior Notes at any time prior to May 1, 2023, at its option, at a redemption price equal to 100% of the principal amount of such 2028 Senior Notes plus the Applicable Premium (as defined in the Indenture). The Company may also redeem up to 40% of the 2028 Senior Notes with the proceeds of certain equity offerings completed before May 1, 2023, at a redemption price equal to 104.25% of the principal amount of such 2028 Senior Notes. On or after May 1, 2023, the Company may on any one or more occasions redeem all or a part of the 2028 Senior Notes, at the redemption prices specified in the Indenture based on the applicable date of redemption. Upon the occurrence of a Change of Control Triggering Event (as defined in the Indenture), the Company will be required to offer to repurchase the Senior Notes at a purchase price equal to 101% of the aggregate principal amount of such Senior Notes. Any redemption of the Senior Notes would also require settlement of accrued and unpaid interest, if any, up to but excluding the redemption date.
Net proceeds from the 2028 Senior Notes of approximately $494 million and available cash were used to prepay a portion of the term loan on October 23, 2019.
Commitment Letter
On February 12, 2018, the Company secured an $830 million commitment under a 364-day senior unsecured bridge loan facility (the Bridge Facility) for the purpose of financing the acquisition of MPI Research. The Bridge Facility was terminated as of April 3, 2018 upon the successful acquisition of MPI Research. Debt issuance costs of $1.8 million, which were capitalized upon the execution of the Bridge Facility, were expensed upon termination of the agreement on April 3, 2018. In addition, the Company incurred and expensed $2.0 million of fees pertaining to a temporary backstop facility related to the negotiation of the Credit Facility during the three months ended March 31, 2018. These costs were included in Interest expense in the accompanying unaudited condensed consolidated statements of income.
Letters of Credit
As of September 28, 2019 and December 29, 2018, the Company had $6.7 million and $6.5 million, respectively, in outstanding letters of credit.
10. EQUITY AND NONCONTROLLING INTERESTS
Earnings Per Share
The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share:
 
Three Months Ended
 
Nine Months Ended
 
September 28, 2019
 
September 29, 2018
 
September 28, 2019
 
September 29, 2018
 
(in thousands)
Numerator:
 
 
 
 
 
 
 
Income from continuing operations, net of income taxes
$
73,552

 
$
60,902

 
$
173,549

 
$
167,020

Income from discontinued operations, net of income taxes

 

 

 
1,506

Less: Net income attributable to noncontrolling interests
742

 
534

 
1,878

 
1,818

Net income attributable to common shareholders
$
72,810

 
$
60,368

 
$
171,671

 
$
166,708

 
 
 
 
 
 
 
 
Denominator:
 
 
 
 
 
 
 
Weighted-average shares outstanding - Basic
48,818

 
48,310

 
48,682

 
48,098

Effect of dilutive securities:
 
 
 
 
 
 
 
Stock options, restricted stock units, performance share units and restricted stock
897

 
1,016

 
945

 
1,020

Weighted-average shares outstanding - Diluted
49,715

 
49,326

 
49,627

 
49,118



27

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)


Options to purchase 0.4 million and 0.5 million shares for the three months ended September 28, 2019 and September 29, 2018, respectively, as well as a non-significant number of restricted shares, restricted stock units (RSUs), and performance share units (PSUs), were not included in computing diluted earnings per share because their inclusion would have been anti-dilutive. Options to purchase 0.4 million and 0.5 million shares for the nine months ended September 28, 2019 and September 29, 2018, respectively, as well as a non-significant number of restricted shares, RSUs and PSUs, were not included in computing diluted earnings per share because their inclusion would have been anti-dilutive. Basic weighted-average shares outstanding for both the nine mont